U.S. stock market anomaly | BeiGene Ltd. (ONC.US) up 6%, institutions believe the innovative pharmaceutical market outlook is expected to continue.

According to the Securities Times app, on Friday, BeiGene (ONC.US) rose by 6%, reaching $338.19. HuaBao Fund emphasized that innovative drugs are still the strongest trend and are expected to continue. Starting in September, key clinical data for Chinese innovative drugs will be released at major conferences in the second half of the year, including the World Lung Cancer Conference, the European Oncology Conference, and the American Blood Conference. In addition, with the arrival of the peak season for authorization by overseas multinational pharmaceutical companies at the end of the year (several Chinese potential BICs are already in the late stages of negotiations), innovative drugs are expected to usher in a market feast similar to the "shining stars of Chinese innovative drug data" at the American Oncology Conference in May of this year in the next quarter.